Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 150

    1.

    Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer.

    Pegram MD, Borges VF, Ibrahim N, Fuloria J, Shapiro C, Perez S, Wang K, Schaedli Stark F, Courtenay Luck N.

    Breast Cancer Res. 2009;11(5):R73. Epub .

    PMID:
    19811637
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer.

    Ibrahim NK, Yariz KO, Bondarenko I, Manikhas A, Semiglazov V, Alyasova A, Komisarenko V, Shparyk Y, Murray JL, Jones D, Senderovich S, Chau A, Erlandsson F, Acton G, Pegram M.

    Clin Cancer Res. 2011 Nov 1;17(21):6822-30. Epub 2011 Aug 30.

    PMID:
    21878535
    [PubMed - indexed for MEDLINE]
    3.

    Final Report on Carcinogens Background Document for Styrene.

    National Toxicology Program.

    Rep Carcinog Backgr Doc. 2008 Sep;(8-5978):i-398.

    PMID:
    20737009
    [PubMed - as supplied by publisher]
    4.

    Final Report on Carcinogens Background Document for Formaldehyde.

    National Toxicology Program.

    Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.

    PMID:
    20737003
    [PubMed - as supplied by publisher]
    5.

    Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

    Plosker GL, Figgitt DP.

    Drugs. 2003;63(8):803-43. Review.

    PMID:
    12662126
    [PubMed - indexed for MEDLINE]
    6.

    Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

    Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA.

    J Clin Oncol. 2010 Jun 1;28(16):2698-704. Epub 2010 Apr 26.

    PMID:
    20421541
    [PubMed - indexed for MEDLINE]
    7.

    Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients.

    Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, Verstraeten AA, Livingston PO, Hilgers J, Kenemans P.

    Int J Cancer. 2001 Jul 1;93(1):97-106.

    PMID:
    11391628
    [PubMed - indexed for MEDLINE]
    8.

    Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer.

    Scholl SM, Balloul JM, Le Goc G, Bizouarne N, Schatz C, Kieny MP, von Mensdorff-Pouilly S, Vincent-Salomon A, Deneux L, Tartour E, Fridman W, Pouillart P, Acres B.

    J Immunother. 2000 Sep-Oct;23(5):570-80.

    PMID:
    11001550
    [PubMed - indexed for MEDLINE]
    9.

    Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.

    Storniolo AM, Pegram MD, Overmoyer B, Silverman P, Peacock NW, Jones SF, Loftiss J, Arya N, Koch KM, Paul E, Pandite L, Fleming RA, Lebowitz PF, Ho PT, Burris HA 3rd.

    J Clin Oncol. 2008 Jul 10;26(20):3317-23. Epub 2008 May 19.

    PMID:
    18490651
    [PubMed - indexed for MEDLINE]
    10.

    Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

    Tokuda Y, Watanabe T, Omuro Y, Ando M, Katsumata N, Okumura A, Ohta M, Fujii H, Sasaki Y, Niwa T, Tajima T.

    Br J Cancer. 1999 Dec;81(8):1419-25.

    PMID:
    10604742
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    11.

    Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

    Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

    Clin Ther. 2003 Jun;25(6):1700-21.

    PMID:
    12860493
    [PubMed - indexed for MEDLINE]
    12.

    A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.

    Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodríguez-Braun E, Domingo A, Guijarro J, Gamez C, Rodon J, Di Cosimo S, Brown H, Clark J, Hardwick JS, Beckman RA, Hanley WD, Hsu K, Calvo E, Roselló S, Langdon RB, Baselga J.

    Clin Cancer Res. 2011 Oct 1;17(19):6304-12. Epub 2011 Aug 2.

    PMID:
    21810918
    [PubMed - indexed for MEDLINE]
    13.

    Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

    Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ.

    J Clin Oncol. 1999 Sep;17(9):2639-48.

    PMID:
    10561337
    [PubMed - indexed for MEDLINE]
    14.

    A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

    Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ.

    Clin Cancer Res. 2003 May;9(5):1639-47.

    PMID:
    12738716
    [PubMed - indexed for MEDLINE]
    Free Article
    15.

    Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.

    Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G.

    J Clin Oncol. 2005 Apr 10;23(11):2534-43. Epub 2005 Feb 7.

    PMID:
    15699478
    [PubMed - indexed for MEDLINE]
    16.

    Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.

    Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, Branstetter D, Burgess TL, Coxon A, Deng H, Kaplan-Lefko P, Leitch IM, Oliner KS, Yan L, Zhu M, Gore L.

    Clin Cancer Res. 2010 Jan 15;16(2):699-710. Epub 2010 Jan 12.

    PMID:
    20068101
    [PubMed - indexed for MEDLINE]
    Free Article
    17.

    Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.

    Guo F, Letrent SP, Munster PN, Britten CD, Gelmon K, Tolcher AW, Sharma A.

    Cancer Chemother Pharmacol. 2008 Jun;62(1):97-109. Epub 2007 Sep 6.

    PMID:
    17805538
    [PubMed - indexed for MEDLINE]
    18.

    Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

    Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L.

    J Clin Oncol. 1996 Mar;14(3):737-44.

    PMID:
    8622019
    [PubMed - indexed for MEDLINE]
    19.

    Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity.

    de Bono JS, Rha SY, Stephenson J, Schultes BC, Monroe P, Eckhardt GS, Hammond LA, Whiteside TL, Nicodemus CF, Cermak JM, Rowinsky EK, Tolcher AW.

    Ann Oncol. 2004 Dec;15(12):1825-33.

    PMID:
    15550589
    [PubMed - indexed for MEDLINE]
    Free Article
    20.

    Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.

    Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, Graziano R, Fisher JL, Meyer L, Mrozek-Orlowski M, et al.

    J Clin Oncol. 1995 Sep;13(9):2281-92.

    PMID:
    7545221
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk